Zoetis Inc. or Geron Corporation: Who Manages SG&A Costs Better?

SG&A Cost Management: Zoetis Inc. vs. Geron Corporation

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Zoetis Inc. and Geron Corporation have shown contrasting approaches. Zoetis, a leader in animal health, consistently maintained higher SG&A expenses, peaking at approximately $2.15 billion in 2023. This reflects their expansive market reach and robust operational scale. In contrast, Geron Corporation, a biopharmaceutical company focused on oncology, exhibited a more conservative SG&A strategy, with expenses rising from $16.8 million in 2014 to $69.1 million in 2023. Despite a 312% increase over the decade, Geron's SG&A costs remain a fraction of Zoetis's, highlighting their leaner operational model. This comparison underscores the diverse strategies in cost management within the industry, influenced by company size, market focus, and growth ambitions.